Key result
GP IIb-IIIa inhibitors (abciximab, eptifibatide, and tirofiban) have distinct pharmacological profiles, with bleeding and thrombocytopenia being the most common safety concerns.
This review highlights the pharmacological differences and common safety concerns (bleeding and thrombocytopenia) among the three approved parenteral GP IIb-IIIa inhibitors.
The introduction of GP IIb‐IIIa inhibitors is one of the most important developments in the treatment of acute coronary syndromes and acute complications of percutaneous coronary syndromes. To date, three parenteral GP IIb‐IIIa inhibitors: abciximab, eptifibatide, and tirofiban have been approved for clinical use. These three agents have different pharmacological characteristics and associated pharmacodynamic and safety profiles. Currently, there is no standardized assay for measurement of inhibition of platelet aggregation, making direct comparisons qf pharmacodynamic properties of GP IIb‐IIIa inhibitors impossible. The most common safety concerns with this class of agents are bleeding and thrombocytopenia.
No takes yet. Share an insight, caveat, or question.
J. David Talley (2000) conducted a review in Acute coronary syndromes and acute complications of percutaneous coronary syndromes. GP IIb-IIIa inhibitors (abciximab, eptifibatide, tirofiban) was evaluated. GP IIb-IIIa inhibitors (abciximab, eptifibatide, and tirofiban) have distinct pharmacological profiles, with bleeding and thrombocytopenia being the most common safety concerns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: